Nucs AI develops AI-driven software for advanced image analysis specifically for prostate cancer management. Their platform provides automated lesion detection, tumor burden quantification, and treatment outcome predictions using PSMA-PET/CT data. This technology streamlines clinical workflows, enhances diagnostic accuracy, and supports personalized therapeutic decision-making for oncologists.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Clinicians face challenges in accurately quantifying tumor burden and predicting treatment outcomes for prostate cancer patients undergoing PSMA-PET/CT imaging. This can lead to ineffective treatments and unnecessary side effects for patients who are unlikely to benefit from specific therapies.
Solution
Nucs AI offers an AI-powered platform that analyzes PSMA-PET/CT scans to provide comprehensive tumor analysis and personalized treatment predictions for prostate cancer. The DeepPSMA module delivers fast, reproducible whole-body tumor burden quantification, offering critical insights into tumor characteristics. The SelectPSMA module uses AI to predict patient outcomes following treatment with PSMA-targeted radiopharmaceuticals, helping clinicians identify patients unlikely to benefit from Pluvicto and avoid futile treatments. By integrating seamlessly into existing clinical workflows, Nucs AI improves efficiency and supports evidence-based decisions for personalized patient care.
Target Audience
The primary users are radiologists and clinicians specializing in prostate cancer care who seek to improve treatment planning and patient selection using advanced image analysis and AI-powered predictions.
Features
- DeepPSMA: AI-driven quantification of whole-body tumor burden from PSMA-PET/CT imaging.
- SelectPSMA: Prediction of patient outcomes following PSMA-targeted radiopharmaceutical therapy.
- Identification of patients unlikely to benefit from Pluvicto, reducing unnecessary treatments.
- Seamless integration into existing clinical workflows.
- Generation of evidence-based reports with actionable insights.
- Secure data input ensuring patient privacy and confidentiality.